Phil Galewitz covers Medicaid, Medicare, long‐term care, hospitals and various state health issues. He has covered the health beat for nearly two decades. He is a board member of the Association of Health Care Journalists. In 2004‐05, he was a Kaiser Media Fellow and wrote about community solutions to the uninsured. Before coming to KHN, he was at The Palm Beach Post and was a national health industry writer for the Associated Press and The Patriot‐ News in Harrisburg, Pa. He has a BA in health planning and administration and a master's in public administration with an emphasis in health policy. | Contact: PGalewitz@kff.org
The managed care industry’s growing role in Medicaid got a boost Monday when the Obama administration approved Texas' plan to shift one million additional recipients into private health plans by 2013.
The former Medicare administrator says the U.S. health care system "isn’t built for modern times," but the health care law will help rein in costs and improve care.
President Barack Obama chose Marilyn Tavenner, a nurse and former hospital executive, to run the agency overseeing Medicare and Medicaid.
State Medicaid directors and health insurers press panel to move people who qualify for both Medicare and Medicaid into private health plans for more efficient care.
Hospitals say the burden of cost-cutting falls on them because they’ll be stuck with the bill for care if Medicaid refuses to pay.
KHN staff writer Phil Galewitz reports that the combination of rising enrollments and the end of federal stimulus funds is forcing a huge spike in state spending on Medicaid, the state-federal program for the poor.
KHN staff writers Jenny Gold and Phil Galewitz report on the new rule, which will make it easier for health care providers to participate in the new models of delivering health care.
But it's unlike the online marketplace required by the federal health law and draws only tepid support from health plans and insurance agents.
Kaiser Health News staff writer Phil Galewitz reports that the biggest cut to Medicare requires pharmaceutical companies to lower the rates for low-income beneficiaries.
Data from a federal website show that denial rates routinely exceed 20 percent and often are much higher.